Hypertriglyceridemia - Common Causes, Prevention and Treatment Strategies

Curr Cardiol Rev. 2018 Mar 14;14(1):67-76. doi: 10.2174/1573403X14666180123165542.


Background: Prevention and treatment of dyslipidemias represent the key issues of Cardiovascular Disease (CVD) prophylaxis. Consequently, the effective management of different types of lipid disorders, including hypertriglyceridemia, should be a priority for the healthcare practitioners (e.g.: cardiology and endocrinology specialists, primary care physicians, dietitians, and pharmacists), who provide medical care, as well as for the patients, who receive this care, and need to be directly engaged in it, in order to improve their outcomes. The aim of this review is to facilitate the translation of current trends in hypertriglyceridemia management into a daily practice. The article focuses on the common causes and consequences of hypertriglyceridemia, and discusses diagnostic evaluation and therapeutic options for patients with high Triglyceride (TG) levels and CVD risk.

Conclusion: This review presents the main practice-related strategies, based on the current guidelines for the management of dyslipidemias and CVD risk, according to the European Society of Cardiology (ESC), the European Atherosclerosis Society (EAS), and the American College of Cardiology (ACC)/American Heart Association (AHA), including both non-pharmacological, and pharmacological approaches. It also addresses the beneficial impact of pharmaceutical Care (PC) interventions on clinical outcomes of patients with lipid disorders and CVD risk (in light of Randomized Controlled Trials (RCT) data), and underlines the importance of close cooperation between physicians and pharmacists, who manage such patients.

Keywords: Cardiovascular Diseases (CVD); Pharmaceutical Care (PC); Triglyceride (TG) levels.; dyslipidemia; hypertriglyceridemia; patient management.

Publication types

  • Review

MeSH terms

  • American Heart Association
  • Cardiovascular Diseases / drug therapy*
  • Dyslipidemias* / pathology
  • Dyslipidemias* / prevention & control
  • Dyslipidemias* / therapy
  • Humans
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors / therapeutic use
  • Hypertriglyceridemia* / etiology
  • Hypertriglyceridemia* / pathology
  • Hypertriglyceridemia* / prevention & control
  • Hypertriglyceridemia* / therapy
  • Risk Assessment
  • Risk Factors
  • United States


  • Hydroxymethylglutaryl-CoA Reductase Inhibitors